The Precision Oncology Workflow represents a comprehensive clinical approach to cancer treatment that integrates multiple data modalities—including genomic profiling, medical imaging, clinical documentation, and multidisciplinary tumor board consultation—to enable personalized, evidence-based therapeutic decision-making. This workflow synthesizes molecular, anatomical, and clinical information to stratify patient risk, identify appropriate clinical trials, and support individualized treatment selection through computational analysis of similar patient cases (N-of-1 analysis).¹⁾

Precision oncology workflows address a fundamental challenge in cancer medicine: significant inter-patient heterogeneity in treatment response and outcomes. Traditional cancer treatment typically relies on histological classification and tumor stage, which inadequately capture the molecular and clinical diversity driving individual patient prognoses and therapeutic responses. The precision oncology workflow consolidates multiple information streams to create a holistic patient profile that enables more targeted clinical decision-making.

The workflow integrates four primary data categories: (1) genomic profiling data identifying molecular drivers (mutations, copy number variations, chromosomal rearrangements); (2) medical imaging providing anatomical context and tumor burden quantification; (3) clinical documentation capturing disease timelines, symptomatology, comorbidities, and prior treatment histories; and (4) tumor board assessment incorporating multidisciplinary expert evaluation. This multimodal integration creates a richer clinical context than any single data source alone can provide.

Genomic profiling forms the molecular foundation of precision oncology workflows, identifying actionable mutations and molecular drivers that may predict treatment sensitivity or resistance. Tumor sequencing identifies somatic mutations in oncogenic pathways, enabling classification of patients into molecular subtypes with distinct treatment implications. Common profiling approaches include targeted gene panels (examining 50-500 genes), whole exome sequencing (WES), and whole genome sequencing (WGS).

Molecular drivers identified through genomic profiling frequently correspond to FDA-approved targeted therapies or clinical trials. For example, EGFR mutations in lung adenocarcinoma predict sensitivity to EGFR tyrosine kinase inhibitors, while BRAF V600E mutations in melanoma indicate likely response to BRAF/MEK inhibitor combinations. Tumor mutational burden (TMB)—the overall count of somatic mutations per megabase—correlates with immunotherapy responsiveness in multiple cancer types and informs checkpoint inhibitor selection.

Additional molecular features profiled include microsatellite instability (MSI) status, tumor mutational signature analysis, and gene expression profiling. These measures provide complementary stratification beyond single-gene mutations, capturing broader mechanistic insights into individual tumor biology.

Medical imaging provides essential anatomical context, enabling precise tumor localization, burden quantification, and assessment of metastatic disease extent. Imaging modalities integrated into precision oncology workflows typically include computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Quantitative imaging biomarkers—such as largest tumor diameter (for RECIST criteria), metabolic SUV measurements, or radiomic features—enable standardized disease assessment and response monitoring.

Radiomics represents an emerging approach extracting high-dimensional quantitative features from imaging data, capturing tumor texture, heterogeneity, and microarchitecture. These radiomic signatures may correlate with molecular subtypes, prognosis, or treatment response, providing an imaging-based complement to genomic data. Integration of imaging features with genomic data enables multi-modal risk stratification potentially more predictive than either modality independently.

Comprehensive clinical documentation—including medical histories, treatment timelines, symptom onset patterns, performance status, comorbidities, and prior therapy responses—provides essential context for treatment selection and outcome prediction. This clinical narrative information captures disease trajectory and individual patient factors influencing therapeutic feasibility and expected tolerability.

Risk stratification algorithms integrate genomic, imaging, and clinical data to predict individual patient outcomes and treatment responsiveness. These algorithms may employ traditional statistical models (Cox proportional hazards regression), machine learning approaches (random forests, gradient boosting), or deep learning architectures processing multimodal inputs. Stratification enables identification of high-risk patients requiring intensified monitoring, intervention, or trial enrollment.

A critical application of precision oncology workflows involves matching patients to appropriate clinical trials based on eligibility criteria, molecular profiles, and disease characteristics. Automated trial-matching algorithms systematically search available trial databases against individual patient molecular and clinical features, identifying opportunities for enrollment in therapeutics targeting identified drivers.

N-of-1 patient similarity analysis represents a complementary approach comparing individual patient profiles against cohorts of similar patients—matched on molecular, imaging, and clinical dimensions—to identify analogous treatment outcomes and responses. This approach enables learning from similar cases to inform individualized prognosis and treatment selection. N-of-1 methods identify patients with similar genomic profiles (e.g., identical driver mutations), comparable imaging burden, and analogous clinical presentations, extracting outcome patterns from comparable cases to contextualize individual predictions.

Multidisciplinary tumor boards—comprising oncologists, surgeons, radiologists, pathologists, and other specialists—provide expert clinical assessment integrating the comprehensive precision oncology workflow data. Tumor boards synthesize genomic profiling results, imaging findings, clinical histories, and trial availability to recommend individualized treatment plans. Computational systems supporting tumor boards organize and present multimodal data efficiently, highlighting key molecular findings and relevant clinical trial opportunities.

Implementation of precision oncology workflows encounters several technical and practical challenges. Data integration across disparate sources (electronic health records, genomic databases, imaging systems, trial registries) requires standardized data models and robust interoperability infrastructure. Computational complexity of multimodal analysis demands significant technical resources and specialized expertise in clinical informatics.

Genomic data interpretation remains challenging given the large proportion of variants of uncertain significance (VUS) in individual patient profiles. Clinical actionability of identified mutations varies substantially; many identified variants lack clear therapeutic or prognostic implications. Integration of genomic data with clinical decision-making requires domain expertise and careful validation.

Regulatory and privacy considerations constrain data integration; genomic data handling requires strict compliance with HIPAA, GDPR, and emerging genetic privacy frameworks. Equitable implementation across diverse populations requires large, representative genomic cohorts to ensure algorithm performance across demographic groups.

Precision oncology workflows increasingly integrate advanced artificial intelligence and machine learning approaches, enabling automated multimodal analysis and outcome prediction at scale. Large oncology centers and academic medical institutions have implemented institutional precision oncology programs, with commercial platforms emerging to support workflow automation. Continued development of federated learning approaches may enable multimodal algorithm development while maintaining privacy constraints across institutional boundaries.

• Chemotherapy vs. Modern Precision Medicine
• Spatial Transcriptomics vs. Current Standard Care
• Biomarker-Driven Treatment Selection